Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Christopher Chang1,2 1New Mexico VA Health Care System, Division of Gastroenterology and Hepatology, Albuquerque, NM, USA; 2Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA Abstract: Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) di...

Full description

Bibliographic Details
Main Author: Chang C
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:Clinical and Experimental Gastroenterology
Subjects:
antibiotic
diarrhea
dysbiosis
gastrointestinal
pain
Xifaxan
Online Access:https://www.dovepress.com/short-course-therapy-for-diarrhea-predominant-irritable-bowel-syndrome-peer-reviewed-article-CEG

Internet

https://www.dovepress.com/short-course-therapy-for-diarrhea-predominant-irritable-bowel-syndrome-peer-reviewed-article-CEG

Similar Items